HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -189.07 Billion KRW | -141.92% |
| 2022 | -78.15 Billion KRW | 20.35% |
| 2021 | -98.12 Billion KRW | -22.51% |
| 2020 | -80.09 Billion KRW | -80.44% |
| 2019 | -44.38 Billion KRW | -275.14% |
| 2018 | 25.34 Billion KRW | 253.31% |
| 2017 | -16.52 Billion KRW | -25.09% |
| 2016 | -13.21 Billion KRW | -204.55% |
| 2015 | 12.63 Billion KRW | 953.32% |
| 2014 | -1.48 Billion KRW | 78.15% |
| 2013 | -6.78 Billion KRW | -29.14% |
| 2012 | -5.25 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -103.25 Billion KRW | -419.88% |
| 2024 Q1 | 32.28 Billion KRW | 127.15% |
| 2023 Q4 | -118.88 Billion KRW | -464.95% |
| 2023 Q2 | -29.24 Billion KRW | -46.92% |
| 2023 Q1 | -19.9 Billion KRW | 45.83% |
| 2023 Q3 | -21.04 Billion KRW | 28.04% |
| 2023 FY | -189.07 Billion KRW | -141.92% |
| 2022 Q3 | -31.94 Billion KRW | -608.39% |
| 2022 Q4 | -36.74 Billion KRW | -15.04% |
| 2022 Q2 | 6.28 Billion KRW | 139.88% |
| 2022 Q1 | -15.75 Billion KRW | 72.68% |
| 2022 FY | -78.15 Billion KRW | 20.35% |
| 2021 Q2 | -31.91 Billion KRW | -73.35% |
| 2021 Q4 | -57.67 Billion KRW | -684.44% |
| 2021 Q3 | 9.86 Billion KRW | 130.92% |
| 2021 FY | -98.12 Billion KRW | -22.51% |
| 2021 Q1 | -18.4 Billion KRW | 18.43% |
| 2020 Q4 | -22.56 Billion KRW | -671.71% |
| 2020 FY | -80.09 Billion KRW | -80.44% |
| 2020 Q2 | -47.83 Billion KRW | -250.71% |
| 2020 Q1 | -13.63 Billion KRW | -184.59% |
| 2020 Q3 | 3.94 Billion KRW | 108.25% |
| 2019 Q2 | -70.66 Billion KRW | -590.04% |
| 2019 FY | -44.38 Billion KRW | -275.14% |
| 2019 Q4 | 16.12 Billion KRW | -20.96% |
| 2019 Q3 | 20.39 Billion KRW | 128.87% |
| 2019 Q1 | -10.24 Billion KRW | -168.74% |
| 2018 Q4 | 14.89 Billion KRW | 298.66% |
| 2018 FY | 25.34 Billion KRW | 253.31% |
| 2018 Q2 | -7.77 Billion KRW | -130.23% |
| 2018 Q1 | 25.71 Billion KRW | 591.3% |
| 2018 Q3 | -7.49 Billion KRW | 3.53% |
| 2017 Q1 | -2.08 Billion KRW | 74.21% |
| 2017 FY | -16.52 Billion KRW | -25.09% |
| 2017 Q4 | -5.23 Billion KRW | 14.27% |
| 2017 Q3 | -6.1 Billion KRW | -96.34% |
| 2017 Q2 | -3.1 Billion KRW | -49.48% |
| 2016 FY | -13.21 Billion KRW | -204.55% |
| 2016 Q4 | -8.06 Billion KRW | -230.65% |
| 2016 Q3 | -2.43 Billion KRW | -21.78% |
| 2016 Q2 | -2 Billion KRW | -184.03% |
| 2016 Q1 | -705.29 Million KRW | -104.04% |
| 2015 Q1 | -802.96 Million KRW | -53.44% |
| 2015 Q4 | 17.47 Billion KRW | 1214.33% |
| 2015 Q3 | -1.56 Billion KRW | 32.84% |
| 2015 Q2 | -2.33 Billion KRW | -190.7% |
| 2015 FY | 12.63 Billion KRW | 953.32% |
| 2014 Q2 | -1.38 Billion KRW | -525.64% |
| 2014 Q4 | -523.3 Million KRW | -615.58% |
| 2014 Q1 | 325.33 Million KRW | 107.71% |
| 2014 FY | -1.48 Billion KRW | 78.15% |
| 2014 Q3 | 101.49 Million KRW | 107.33% |
| 2013 Q1 | -1.44 Billion KRW | 2.85% |
| 2013 Q3 | 592.63 Million KRW | 134.7% |
| 2013 FY | -6.78 Billion KRW | -29.14% |
| 2013 Q4 | -4.22 Billion KRW | -812.09% |
| 2013 Q2 | -1.7 Billion KRW | -18.22% |
| 2012 Q4 | -1.48 Billion KRW | 53.14% |
| 2012 FY | -5.25 Billion KRW | 0.0% |
| 2012 Q3 | -3.17 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -1850.194% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 4148.16% |
| Bioneer Corporation | -10.58 Billion KRW | -1685.953% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -6555.733% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 3337.661% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | -286.479% |
| Helixmith Co., Ltd | -64.08 Billion KRW | -195.029% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -2142.603% |
| Medy-Tox Inc. | 9.75 Billion KRW | 2038.262% |
| Peptron, Inc. | -15.92 Billion KRW | -1087.544% |
| Amicogen, Inc. | -23.28 Billion KRW | -711.886% |
| Genexine, Inc. | -66.87 Billion KRW | -182.742% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -8113.135% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | -156.54% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -5507.729% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 346.997% |
| SillaJen, Inc. | -20.36 Billion KRW | -828.259% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 1453.863% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | -889.856% |
| Genomictree Inc. | -8.75 Billion KRW | -2059.417% |
| MedPacto, Inc. | -35.32 Billion KRW | -435.26% |
| D&D Pharmatech | 3.93 Billion KRW | 4906.527% |
| EASY BIO,Inc. | 15.54 Billion KRW | 1316.431% |
| GI Innovation, Inc. | -55.49 Billion KRW | -240.712% |